
Trade-Ideas: Exelixis (EXEL) Is Today's Strong On High Relative Volume Stock
Trade-Ideas LLC identified
(
) as a strong on high relative volume candidate. In addition to specific proprietary factors, Trade-Ideas identified Exelixis as such a stock due to the following factors:
- EXEL has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $43.2 million.
- EXEL has traded 807,334 shares today.
- EXEL is trading at 2.11 times the normal volume for the stock at this time of day.
- EXEL is trading at a new high 3.03% above yesterday's close.
'Strong on High Relative Volume' stocks are worth watching because major volume moves tend to indicate underlying activity such as M&A events, material stock news, analyst upgrades, insider buying, buying from 'superinvestors,' or that hedge funds and momentum traders are piling into a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize. In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in EXEL with the Ticky from Trade-Ideas. See the FREE profile for EXEL NOW at Trade-Ideas
More details on EXEL:
Exelixis, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule therapies for the treatment of cancer in the United States and the European Union. Currently there are 4 analysts that rate Exelixis a buy, no analysts rate it a sell, and 1 rates it a hold.
The average volume for Exelixis has been 4.8 million shares per day over the past 30 days. Exelixis has a market cap of $1.6 billion and is part of the health care sector and drugs industry. The stock has a beta of 1.75 and a short float of 28.9% with 8.30 days to cover. Shares are up 28.7% year-to-date as of the close of trading on Wednesday.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Analysis:
rates Exelixis as a
. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income and feeble growth in its earnings per share.
Highlights from the ratings report include:
- The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Biotechnology industry. The net income has significantly decreased by 74.4% when compared to the same quarter one year ago, falling from -$35.17 million to -$61.35 million.
- EXELIXIS INC's earnings per share declined by 50.0% in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. We feel it is likely to report a decline in earnings in the coming year. During the past fiscal year, EXELIXIS INC continued to lose money by earning -$0.81 versus -$1.39 in the prior year. For the next year, the market is expecting a contraction of 8.6% in earnings (-$0.88 versus -$0.81).
- Compared to its closing price of one year ago, EXEL's share price has jumped by 102.39%, exceeding the performance of the broader market during that same time frame. Regarding the future course of this stock, we feel that the risks involved in investing in EXEL do not compensate for any future upside potential, despite the fact that it has seen nice gains over the past 12 months.
- Net operating cash flow has significantly increased by 443.55% to $154.90 million when compared to the same quarter last year. In addition, EXELIXIS INC has also vastly surpassed the industry average cash flow growth rate of 12.58%.
- EXEL's very impressive revenue growth greatly exceeded the industry average of 18.1%. Since the same quarter one year prior, revenues leaped by 64.3%. This growth in revenue does not appear to have trickled down to the company's bottom line, displayed by a decline in earnings per share.
- You can view the full Exelixis Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.









